Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
仑伐替尼联合帕博利珠单抗对比舒尼替尼在晚期肾细胞癌一线治疗中的应用:III 期临床研究 CLEAR 的最终预设总生存期分析
期刊:Journal of Clinical Oncology
影响因子:42.1
doi:10.1200/JCO.23.01569
Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, María José Méndez-Vidal, Evgeny Kopyltsov, Sergei Tjulandin,